Successfully Navigating Opportunities With On-Body Delivery Systems – Common Questions And Answers

By Di Wu and Cate Vora

In today’s rapidly advancing drug delivery landscape, on-body delivery systems (OBDS) have emerged as a highly sophisticated class of combination products, seamlessly integrating device engineering with pharmaceutical innovation. These systems enable patients to self-administer larger-volume therapies comfortably at home, reducing reliance on clinical settings and expanding access to treatment.

A key advantage of OBDS is their ability to deliver pre-programmed doses at precise intervals with minimal user interaction. This not only simplifies the patient experience but also supports adherence to prescribed regimens — an essential factor in achieving consistent, positive clinical outcomes.

To explore this evolving space, West recently hosted a webinar with Dr. Di Wu, Navigating the Future of Drug Delivery with On-Body Delivery Systems: Harnessing Innovation for Enhanced Patient Outcomes and Regulatory Success. The session examined regulatory pathways in both the U.S. and EU, highlighting critical considerations for successful submissions and market approval.

Drawing on insights from the global regulatory landscape, industry trends, and direct feedback from customers, the following section addresses some of the most frequently asked questions about on-body delivery system requirements.